The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden.

Show simple item record

dc.contributor.author Kapetanovic, Meliha C en
dc.contributor.author Nilsson, Peter en
dc.contributor.author Turesson, Carl en
dc.contributor.author Englund, Martin en
dc.contributor.author Dalbeth, Nicola en
dc.contributor.author Jacobsson, Lennart en
dc.date.accessioned 2019-03-27T21:09:04Z en
dc.date.issued 2018-08-29 en
dc.identifier.citation Arthritis research & therapy 20(1):190 29 Aug 2018 en
dc.identifier.issn 1478-6354 en
dc.identifier.uri http://hdl.handle.net/2292/46298 en
dc.description.abstract BACKGROUND:Hyperuricemia (HU) is in the causal pathway for developing clinical gout. There are few population-based assessments of the absolute and relative risk of clinically diagnosed incident gout in subjects with HU. We aimed to explore the long-term risk of developing incident gout among asymptomatic adults with different levels of serum urate (SU). METHODS:Malmö Preventive Project was a population-based screening program for cardiovascular risk factors, alcohol abuse, and breast cancer in Malmö, Sweden. The study population was screened between 1974 and 1992. At baseline, subjects were assessed with a questionnaire, physical examination, and laboratory tests. Follow-up ended at first gout diagnosis, death, moving from area, or December 31, 2014. Incident gout (using ICD10 codes) was diagnosed based on national registers for specialized inpatient and outpatient care, and from 1998 onward in the Skåne Healthcare Register including primary healthcare. Incidence rates, absolute risk, hazard ratios (HRs) and potentially associated factors were analyzed by baseline SU levels, i.e. normal levels (≤ 360 μmol/L); 361-405 (levels below tissue solubility of SU), and > 405 (HU), overall, and by sex. RESULTS:Overall, 1275 individuals [3.8%; 1014 men (4.5%) and 261 women (2.4%)] of the 33,346 study participants (mean age: 45.7 (SD: 7.4), 67% men), developed incident gout during follow-up (mean 28.2 years). Of those with HU, 14.7% of men and 19.5% of women developed gout. Compared to subjects in the lowest SU category, the age-adjusted HR in men increased from 2.7 to 6.4, and in women from 4.4 to 13.1 with increasing baseline SU category, and with a statistically significant interaction of sex (p < 0.001). Body mass index, estimated glomerular filtration rate (negative), triglycerides, alcohol risk behavior (only in men), and comorbidities such as hypertension, cardiovascular disease, and diabetes were strongly associated with SU at baseline in both sexes. CONCLUSIONS:The absolute risk for developing clinically diagnosed gout over 30 years in middle-aged subjects was 3.8%, and increased progressively in both men and women in relation to baseline SU. This risk increase was significantly higher in women than in men, whereas the associations between baseline risk markers and SU levels were similar in both sexes. en
dc.format.medium Electronic en
dc.language eng en
dc.relation.ispartofseries Arthritis research & therapy en
dc.rights Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. en
dc.rights.uri https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm en
dc.rights.uri https://creativecommons.org/licenses/by/4.0/ en
dc.subject Humans en
dc.subject Gout en
dc.subject Hyperuricemia en
dc.subject Uric Acid en
dc.subject Mass Screening en
dc.subject Risk Factors en
dc.subject Cohort Studies en
dc.subject Follow-Up Studies en
dc.subject Preventive Medicine en
dc.subject Sex Factors en
dc.subject Adult en
dc.subject Middle Aged en
dc.subject Sweden en
dc.subject Female en
dc.subject Male en
dc.title The risk of clinically diagnosed gout by serum urate levels: results from 30 years follow-up of the Malmö Preventive Project cohort in southern Sweden. en
dc.type Journal Article en
dc.identifier.doi 10.1186/s13075-018-1697-6 en
pubs.issue 1 en
pubs.begin-page 190 en
pubs.volume 20 en
dc.rights.holder Copyright: The authors en
pubs.publication-status Published en
dc.rights.accessrights http://purl.org/eprint/accessRights/OpenAccess en
pubs.subtype Research Support, Non-U.S. Gov't en
pubs.subtype research-article en
pubs.subtype Journal Article en
pubs.elements-id 753510 en
pubs.org-id Medical and Health Sciences en
pubs.org-id School of Medicine en
pubs.org-id Medicine Department en
dc.identifier.eissn 1478-6362 en
pubs.record-created-at-source-date 2018-08-31 en
pubs.dimensions-id 30157929 en


Files in this item

Find Full text

This item appears in the following Collection(s)

Show simple item record

Share

Search ResearchSpace


Browse

Statistics